Titre : Molécules d'interaction stromale

Molécules d'interaction stromale : Questions médicales fréquentes

Termes MeSH sélectionnés :

Placenta
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Molécules d'interaction stromale : Questions médicales les plus fréquentes", "headline": "Molécules d'interaction stromale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Molécules d'interaction stromale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Molécules d'interaction stromale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines membranaires", "url": "https://questionsmedicales.fr/mesh/D008565", "about": { "@type": "MedicalCondition", "name": "Protéines membranaires", "code": { "@type": "MedicalCode", "code": "D008565", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Molécule-1 d'interaction stromale", "alternateName": "Stromal Interaction Molecule 1", "url": "https://questionsmedicales.fr/mesh/D000071737", "about": { "@type": "MedicalCondition", "name": "Molécule-1 d'interaction stromale", "code": { "@type": "MedicalCode", "code": "D000071737", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.875.500" } } }, { "@type": "MedicalWebPage", "name": "Molécule-2 d'interaction stromale", "alternateName": "Stromal Interaction Molecule 2", "url": "https://questionsmedicales.fr/mesh/D000071738", "about": { "@type": "MedicalCondition", "name": "Molécule-2 d'interaction stromale", "code": { "@type": "MedicalCode", "code": "D000071738", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.875.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Molécules d'interaction stromale", "alternateName": "Stromal Interaction Molecules", "code": { "@type": "MedicalCode", "code": "D000071736", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Peter B Stathopulos", "url": "https://questionsmedicales.fr/author/Peter%20B%20Stathopulos", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca." } }, { "@type": "Person", "name": "Paul Sohn", "url": "https://questionsmedicales.fr/author/Paul%20Sohn", "affiliation": { "@type": "Organization", "name": "Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN." } }, { "@type": "Person", "name": "Wenting Wu", "url": "https://questionsmedicales.fr/author/Wenting%20Wu", "affiliation": { "@type": "Organization", "name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN." } }, { "@type": "Person", "name": "Marjan Slak Rupnik", "url": "https://questionsmedicales.fr/author/Marjan%20Slak%20Rupnik", "affiliation": { "@type": "Organization", "name": "Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria." } }, { "@type": "Person", "name": "Chih-Chun Lee", "url": "https://questionsmedicales.fr/author/Chih-Chun%20Lee", "affiliation": { "@type": "Organization", "name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interactions between ultrasonographic cervical length and placenta accreta spectrum on severe postpartum hemorrhage in women with placenta previa.", "datePublished": "2023-01-09", "url": "https://questionsmedicales.fr/article/36572390", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijgo.14641" } }, { "@type": "ScholarlyArticle", "name": "Risk of preterm birth for placenta previa or low-lying placenta and possible preventive interventions: A systematic review and meta-analysis.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36120450", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2022.921220" } }, { "@type": "ScholarlyArticle", "name": "Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36075058", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/AOG.0000000000004923" } }, { "@type": "ScholarlyArticle", "name": "Serotonin system in the human placenta - the knowns and unknowns.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/36531448", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2022.1061317" } }, { "@type": "ScholarlyArticle", "name": "Research progress on N6-methyladenosine in the human placenta.", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35606944", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1515/jpm-2021-0665" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Molécules d'interaction stromale", "item": "https://questionsmedicales.fr/mesh/D000071736" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Molécules d'interaction stromale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Molécules d'interaction stromale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Molécules d'interaction stromale", "description": "Comment diagnostiquer une interaction stromale ?\nQuels tests sont utilisés pour les molécules stromales ?\nLes marqueurs stromaux sont-ils spécifiques ?\nPeut-on détecter les molécules stromales par imagerie ?\nQuel rôle joue la biopsie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Molécules d'interaction stromale", "description": "Quels symptômes sont liés aux interactions stromales ?\nLes interactions stromales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les tumeurs ?\nLes symptômes sont-ils précoces ou tardifs ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Molécules d'interaction stromale", "description": "Peut-on prévenir les interactions stromales ?\nQuels modes de vie aident à prévenir les tumeurs ?\nLes dépistages réguliers sont-ils utiles ?\nL'éducation sur le cancer est-elle importante ?\nLes vaccins peuvent-ils prévenir les tumeurs ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Molécules d'interaction stromale", "description": "Quels traitements ciblent les molécules stromales ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires des traitements ?\nComment les traitements sont-ils personnalisés ?\nLes traitements sont-ils combinés ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Molécules d'interaction stromale", "description": "Quelles complications peuvent survenir ?\nLes interactions stromales aggravent-elles les complications ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Molécules d'interaction stromale", "description": "Quels sont les facteurs de risque des interactions stromales ?\nL'alimentation influence-t-elle les risques ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un risque ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Placenta&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une interaction stromale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les molécules stromales ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale." } }, { "@type": "Question", "name": "Les marqueurs stromaux sont-ils spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux." } }, { "@type": "Question", "name": "Peut-on détecter les molécules stromales par imagerie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux interactions stromales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale." } }, { "@type": "Question", "name": "Les interactions stromales causent-elles des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les tumeurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique." } }, { "@type": "Question", "name": "Les symptômes sont-ils précoces ou tardifs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales." } }, { "@type": "Question", "name": "Peut-on prévenir les interactions stromales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation." } }, { "@type": "Question", "name": "Quels modes de vie aident à prévenir les tumeurs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales." } }, { "@type": "Question", "name": "L'éducation sur le cancer est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les tumeurs ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés." } }, { "@type": "Question", "name": "Quels traitements ciblent les molécules stromales ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie selon le type de tumeur et la nature des interactions stromales." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires." } }, { "@type": "Question", "name": "Comment les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal." } }, { "@type": "Question", "name": "Les traitements sont-ils combinés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la progression tumorale, la résistance au traitement et la métastase." } }, { "@type": "Question", "name": "Les interactions stromales aggravent-elles les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque des interactions stromales ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer l'inflammation et augmenter le risque de complications." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales." } }, { "@type": "Question", "name": "L'exposition à des toxines est-elle un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer." } } ] } ] }

Sources (2956 au total)

Interactions between ultrasonographic cervical length and placenta accreta spectrum on severe postpartum hemorrhage in women with placenta previa.

To explore the interactions between cervical length (CL) and placenta accreta spectrum (PAS) on severe postpartum hemorrhage (SPPH) in patients with placenta previa.... A retrospective case-control study was conducted at four medical centers in China, and 588 patients with placenta previa were included. The logistic regression analysis and restricted cubic splines (R... After adjusting for potential confounders, the negative linear dose-response relationship was confirmed by RCS, and the change of odds ratio (OR) was more significant when CL was 2.5 cm or less. The r... If CL was routinely performed during PAS evaluation, the increased OR of short CL and PAS could allow better patient preparation through counseling....

Risk of preterm birth for placenta previa or low-lying placenta and possible preventive interventions: A systematic review and meta-analysis.

To investigate the risk of preterm birth in women with a placenta previa or a low-lying placenta for different cut-offs of gestational age and to evaluate preventive interventions.... MEDLINE, EMBASE, CENTRAL, Web of Science, WHO-ICTRP and clinicaltrials.gov were searched until December 2021. Randomized controlled trials, cohort studies and case-control studies assessing preterm bi... In total, 34 studies were included, 24 reporting on preterm birth and 9 on preventive interventions. The pooled proportions were 46% (95% CI [39 - 53%]), 17% (95% CI [11 - 25%]), 10% (95% CI [7 - 13%]... Both women with a placenta previa and a low-lying placenta have an increased risk of preterm birth. This increased risk is consistent across all severities of preterm birth between 28-37 weeks of gest... PROSPERO https://www.crd.york.ac.uk/prospero/, identifier CRD42019123675....

Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis.

To evaluate whether there are differences in risk factors and maternal outcomes of pregnancies complicated by placenta accreta spectrum depending on the presence or absence of placenta previa.... We performed a systematic search in Medline, EMBASE, ClinicalTrials.gov , and Web of Science from inception through April 25, 2022, without language or date restrictions. Search strategy included the ... Of the 1,122 articles screened, seven studies were included in the final review. Studies were included if they compared the risk factors and maternal outcomes of pregnancies complicated by placenta ac... A random-effects model was used to pool the mean differences or odds ratios (OR) and the corresponding 95% CIs using RevMan software. A total of 3,342 pregnancies complicated by placenta accreta spect... Pregnancies complicated by placenta accreta spectrum without previa had a more prominent association with IVF and prior D&C and myomectomy but were much less likely to be associated with prior cesarea... PROSPERO, CRD42022307637....

Research progress on N6-methyladenosine in the human placenta.

N6-methyladenosine (m6A) is one of the most common epigenetic modifications of eukaryotic RNA. Under the jointly reversible regulation of related enzymes, m6A regulates many aspects of RNA, such as tr... Data were compiled from 2018 to 2021 citations in PubMed and Google Scholar using the keywords: placenta AND N6-methyladenosine. Seven studies were included.... In this study, we introduced some conventional methods to detect m6A modification at the whole RNA, region (peak) and single base levels. We also summarized the current studies of m6A modification in ... Although the relevant reports are still in the preliminary stage and some results are inconsistent, studies on methylation m6A modification have contributed new ideas for the research of reproductive ...

Placenta Accreta Spectrum Disorders: A National Survey.

Describe the current practice of Canadian obstetricians-gynaecologists in managing placenta accreta spectrum (PAS) disorders from suspicion of diagnosis to delivery planning and explore the impact of ... We distributed a cross-sectional bilingual electronic survey to Canadian obstetricians-gynaecologists in March-April 2021. Demographic data and information on screening, diagnosis, and management were... We received 142 responses. Almost 60% of respondents said they had read the latest Society of Obstetricians and Gynaecologists of Canada clinical practice guideline on PAS disorders, published in July... This study demonstrates the impact of the Society of Obstetricians and Gynaecologists of Canada's PAS clinical practice guideline on management choices made by Canadian clinicians. Our study highlight...